Skip to main content
. Author manuscript; available in PMC: 2015 Jan 13.
Published in final edited form as: J Allergy Clin Immunol. 2008 Dec 12;123(4):861–7.e1. doi: 10.1016/j.jaci.2008.10.036

FIG 1.

FIG 1

Changes in FEV1 (A), FEV1/ FVC (B), FEF25–75 (C), and XA (D) over time are displayed for three treatment groups as both mean data at each measurement point (dashed lines) and as a regression model with a change point at 12 weeks (solid lines). The statistical analyses using the regression model are summarized in Tables I and II. Over the first 12 weeks of therapy, the slopes for FEV1, FEV1/ FVC, and FEF25–75 were significant in a positive direction for combination and fluticasone therapy. However, for these spirometric parameters, the pattern over the last period of therapy (12–48 weeks) was different with all slopes close to zero. Conversely, XA significantly improved in the fluticasone group during the latter period as reflected by the negative slope for change in XA.